Detalhe da pesquisa
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582092
2.
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
Breast Cancer Res Treat
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635082
3.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 205(3): 589-598, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456970
4.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587643
5.
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact.
Breast Cancer Res Treat
; 199(3): 445-456, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043108
6.
Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
Mod Pathol
; 35(8): 1066-1074, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35177782
7.
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
J Peripher Nerv Syst
; 27(2): 166-174, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35384143
8.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019819
9.
The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Breast Cancer Res Treat
; 189(1): 111-120, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34089119
10.
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Breast Cancer Res Treat
; 185(3): 657-666, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33068198
11.
Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.
Hum Mutat
; 41(12): 2128-2142, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32906215
12.
Does multilocus inherited neoplasia alleles syndrome have severe clinical expression?
J Med Genet
; 56(8): 521-525, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30580288
13.
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
Clin Transl Oncol
; 2024 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38519708
14.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575192
15.
Lytic lesions in a patient with past history of renal cancer.
Arch Esp Urol
; 66(3): 302-4, 2013 Apr.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-23648750
16.
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022).
Clin Transl Oncol
; 25(9): 2647-2664, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37326826
17.
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
Clin Cancer Res
; 29(1): 110-121, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282874
18.
BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort.
Genes (Basel)
; 12(2)2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33498765
19.
Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Expert Opin Biol Ther
; 20(9): 981-989, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32450725
20.
ERCC3, a new ovarian cancer susceptibility gene?
Eur J Cancer
; 141: 1-8, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33125943